Jim O’Neill, Trump’s pick to be deputy secretary of HHS, criticized the FDA's drug approval process as overly cautious while directing a Thiel-founded VC firm that invests in biotech companies.
James Clyburn's new senior advisor is returning to Congress after a stint as a registered lobbyist for the health insurance giant.
The pharmaceutical industry has a chance to call the shots as it works to undermine drug pricing negotiations with its favorite, Kentucky Republican Brett Guthrie, heading the Energy and Commerce Committee.
We run down the recipients of drugmaker donations revealed in PhRMA's latest tax filing.
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
Susie Wiles of Mercury Public Affairs, a senior advisor to Trump's campaign, is lobbying for Swisher as it fights a proposal meant to reduce youth smoking.
The maker of Ozempic and Wegovy has recently hired a dozen new lobbyists to work on the issue of obesity and medication coverage.
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
As a consumer protection subcommittee chairman, Blumenthal has focused on the role pharmaceutical benefit managers play in driving up the cost of drugs.
Lobbying giant PhRMA reported revenues of more than $600 million in 2021, a new record for the group.
